Regulatory News:
Commenting on the first quarter 2014 performance, Marc de Garidel, Chairman and Chief Executive Officer of Ipsen said: “Ipsen is off to a good start this year with solid specialty care growth, up 6.4%1, notably driven by the good performance of Somatuline® and Dysport® and the return to growth of Decapeptyl® in China.
Help employers find you! Check out all the jobs and post your resume.
